Linking the sepsis triad of inflammation, coagulation, and suppressed fibrinolysis to infants.
Sepsis continues to be a significant cause of morbidity and mortality in hospitalized newborns and premature infants. The pathophysiology and disease state of sepsis appear to be similar between adults and children. Both groups display symptoms that indicate a systemic inflammatory response leading to coagulopathy, hypotension, inadequate perfusion of peripheral tissues and organs, and, ultimately, organ failure and death. By presenting a comparison of adult and neonatal pathophysiology, as well as a supporting literature review and clinical evidence, this article links the pathways of inflammation, activation of coagulation, and impaired fibrinolysis, known as the sepsis cascade, to neonatal sepsis. Knowledge of the pathophysiology has important clinical and research implications. Unlike traditional antimicrobial therapy, new potential therapies, currently under investigation for the treatment of sepsis, target the cellular response rather than the invading organism. A more complete understanding of the pathophysiology of sepsis may also lead to diagnostic tools with improved sensitivity and specificity for early recognition and treatment.
Short
Mary A
MA
Acute Care Division, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Ind, USA. mshort@lilly.com
D000328:Adult; D001778:Blood Coagulation Disorders / Q000378:metabolism / Q000503:physiopathology*; D002648:Child; D018450:Disease Progression; D005342:Fibrinolysis; D006801:Humans; D007022:Hypotension / Q000503:physiopathology; D007231:Infant, Newborn; D007249:Inflammation / Q000378:metabolism / Q000503:physiopathology*; D018836:Inflammation Mediators / Q000378:metabolism; D015931:Intensive Care, Neonatal / Q000379:methods; D009102:Multiple Organ Failure / Q000378:metabolism / Q000503:physiopathology*; D017283:Neonatal Nursing / Q000379:methods; D012307:Risk Factors; D018805:Sepsis / Q000150:complications / Q000378:metabolism / Q000503:physiopathology* / Q000628:therapy; D016896:Treatment Outcome; D014481:United States
D018836:Inflammation Mediators